LON:CLIN Clinigen Group Share Forecast, Price & News Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat Daily Premium to add more stocks to your watchlist. Adding Clinigen Group plc Please log in to your account or sign up in order to add this asset to your watchlist. GBX 925 0.00 (0.00%) (As of 04/4/2022) Add Compare Share Today's Range 925▼ 92550-Day Range 925▼ 92552-Week Range 541.50▼ 948.05Volume539,375 shsAverage Volume1.83 million shsMarket Capitalization£1.23 billionP/E Ratio64.69Dividend Yield0.82%Price TargetGBX 740 ProfileAnalyst RatingsChartCompetitorsDividendEarningsInsider TradesHeadlines View Price History Chart DataSkip Price History Chart 30 days | 90 days | 365 days | Advanced Chart Receive CLIN Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Clinigen Group and its competitors with MarketBeat's FREE daily newsletter. Email Address CLIN Stock Forecast (MarketRank)Overall MarketRank™1.43 out of 5 starsAnalyst Opinion: 1.3Community Rank: 5.0Dividend Strength: 0.8Insider Behavior: 0.0Valuation: 0.0 5 -4 -3 -2 -1 - 1.3 Analyst's Opinion Consensus RatingClinigen Group has received a consensus rating of Moderate Buy. The company's average rating score is 2.60, and is based on 3 buy ratings, 2 hold ratings, and no sell ratings.Price Target Upside/DownsideAccording to analysts' consensus price target of GBX 740, Clinigen Group has a forecasted downside of 20.0% from its current price of GBX 925.Amount of Analyst CoverageClinigen Group has received no research coverage in the past 90 days. Previous Next 5.0 Community Rank Outperform VotesClinigen Group has received 430 “outperform” votes. (Add your “outperform” vote.)Underperform VotesClinigen Group has received 62 “underperform” votes. (Add your “underperform” vote.)Community SentimentClinigen Group has received 87.40% “outperform” votes from our community.MarketBeat's community ratings are surveys of what our community members think about Clinigen Group and other stocks. Vote “Outperform” if you believe CLIN will outperform the S&P 500 over the long term. Vote “Underperform” if you believe CLIN will underperform the S&P 500 over the long term. You may vote once every thirty days. Previous Next 0.8 Dividend Strength Dividend YieldClinigen Group has a dividend yield of 0.82%, which is in the bottom 25% of all stocks that pay dividends.Dividend GrowthClinigen Group does not have a long track record of dividend growth.Dividend CoverageThe dividend payout ratio of Clinigen Group is 0.53%. This payout ratio is at a healthy, sustainable level, below 75%. Previous Next 0.0 Company Ownership Insider Buying vs. Insider SellingIn the past three months, Clinigen Group insiders have not sold or bought any company stock. Previous Next 0.0 Earnings and Valuation Price to Earnings Ratio vs. the MarketThe P/E ratio of Clinigen Group is 64.69, which means that it is trading at a more expensive P/E ratio than the market average P/E ratio of about 25.23.Price to Earnings Ratio vs. SectorThe P/E ratio of Clinigen Group is 64.69, which means that it is trading at a more expensive P/E ratio than the Medical sector average P/E ratio of about 26.27.Price to Book Value per Share RatioClinigen Group has a P/B Ratio of 2.71. P/B Ratios below 3 indicates that a company is reasonably valued with respect to its assets and liabilities. Previous Next See Top Rated MarketRank™ Stocks Here About Clinigen Group (LON:CLIN)Clinigen Group plc operates as a pharmaceutical and services company in the United Kingdom, rest of Europe, the United States, South Africa, Australia, and internationally. It operates through Services and Products divisions. The company provides a set of niche and high value services to pharma and biotech clients prior to product launch. It also provides access to critical medicines around the world for patients with unmet needs. In addition, the company provides a portfolio of specialist medicines to service the needs of healthcare professionals and their patients in both licensed and unlicensed markets. Further, it offers Nortriptyline Colonis for the treatment of depressive disorder; Metformin Colonis for the treatment of type 2 diabetes mellitus; Magnesium Chewable Tablets, an oral magnesium supplements for the treatment of patients with chronic magnesium loss; Iloprost, a concentrate for solution for infusion; Glycopyrronium Bromide, an oral solution for the treatment of severe sialorrhoea; Acetylcysteine, an oral solution for the treatment of respiratory disorders associated with thick, viscous, and mucus hypersecretion; Cardioxane that protects the heart against the cardiotoxic effects of anthracyclines; Ethyol, which protect against the harmful effects of chemotherapy medications and radiation treatment; Proleukin for the treatment of kidney cancer; Imukin that is used in chronic granulomatous disease; Totect, a dexrazoxane product; Foscavir, an anti-virals that work by stopping viruses from multiplying in number; and Savene, which is indicated in adults for the treatment of anthracycline extravasation. The company was incorporated in 2008 and is headquartered in Burton-on-Trent, the United Kingdom.Read More CLIN Stock News HeadlinesMay 24, 2022 | apnews.comClinigen expands US site capacity in response to growing demand for Clinical Supplies Management servicesMay 24, 2022 | seekingalpha.comClinigen to open 2 satellite facilities to boost clinical supplies management servicesMay 17, 2022 | proactiveinvestors.com'Barbarians' inside the gates: how private equity is raiding the infrastructure sectorMay 5, 2022 | finance.yahoo.comTake-privates in the UK: PE's big British bingeMarch 25, 2022 | finanznachrichten.deSamson Rock Capital LLP - Form 8.3 - Clinigen Group PLCMarch 9, 2022 | benzinga.comEnzyme Replacement Therapy Market Size [2022-2028] worth USD 20.58 Billion | exhibiting a CAGR of 8.8%February 10, 2022 | finance.yahoo.comHumanigen Launches Managed Access Program for LenzilumabJanuary 18, 2022 | finance.yahoo.comElliott Investment Management, L.P: Form 8.3 - Clinigen Group PLCJanuary 18, 2022 | lse.co.ukTriton increases takeover bid for Clinigen to GBP1.3 billionJanuary 17, 2022 | msn.comPrivate equity group Triton sweetens offer for Clinigen in last ditch effort to win over sceptical shareholdersJanuary 17, 2022 | nasdaq.comUK's Clinigen agrees to sweetened $1.8 bln Triton take-private dealJanuary 17, 2022 | bloomberg.comTriton Sweetens Bid for Clinigen to Persuade Biggest InvestorsJanuary 14, 2022 | msn.comAll eyes on pharma firm Clinigen with investors set to vote on its £1.2bn takeover by private equity shark Triton Investment ManagementSee More Headlines Industry, Sector and Symbol Stock ExchangeLON Industry Drug Delivery Sub-IndustryN/A SectorMedical Current SymbolLON:CLIN CUSIPN/A CIKN/A Webwww.clinigengroup.com Phone+44-1283-495010FaxN/AEmployees1,000Year FoundedN/ACompany Calendar Last Earnings9/17/2020Today6/29/2022Price Target and Rating Average Stock Price ForecastGBX 740 High Stock Price ForecastGBX 860 Low Stock Price ForecastGBX 650 Forecasted Upside/Downside-20.0%Consensus RatingModerate Buy Rating Score (0-4)2.6 Research Coverage5 Analysts Profitability EPS (Most Recent Fiscal Year)N/A Trailing P/E Ratio64.69 Forward P/E Ratio0.36 P/E GrowthN/ANet IncomeN/A Net MarginsN/A Pretax MarginN/A Return on EquityN/A Return on AssetsN/A Debt Debt-to-Equity Ratio90.77 Current Ratio1.89 Quick Ratio1.48 Sales & Book Value Annual Sales£565.60 million Price / Sales2.18 Cash FlowGBX 88.30 per share Price / Cash Flow10.48 Book ValueGBX 341.90 per share Price / Book2.71Miscellaneous Outstanding Shares133,367,000Free FloatN/AMarket Cap£1.23 billion OptionableNot Optionable BetaN/A Clinigen Group Frequently Asked Questions Should I buy or sell Clinigen Group stock right now? 5 Wall Street equities research analysts have issued "buy," "hold," and "sell" ratings for Clinigen Group in the last twelve months. There are currently 2 hold ratings and 3 buy ratings for the stock. The consensus among Wall Street equities research analysts is that investors should "moderate buy" Clinigen Group stock. View analyst ratings for Clinigen Group or view top-rated stocks. What is Clinigen Group's stock price forecast for 2022? 5 Wall Street analysts have issued 1 year target prices for Clinigen Group's shares. Their CLIN stock forecasts range from GBX 650 to GBX 860. On average, they expect Clinigen Group's stock price to reach GBX 740 in the next twelve months. This suggests that the stock has a possible downside of 20.0%. View analysts' price targets for Clinigen Group or view top-rated stocks among Wall Street analysts. How has Clinigen Group's stock performed in 2022? Clinigen Group's stock was trading at GBX 915.50 at the beginning of 2022. Since then, CLIN shares have increased by 1.0% and is now trading at GBX 925. View the best growth stocks for 2022 here. How were Clinigen Group's earnings last quarter? Clinigen Group plc (LON:CLIN) announced its quarterly earnings data on Thursday, September, 17th. The company reported $65.60 earnings per share (EPS) for the quarter, beating the consensus estimate of $63.50 by $2.10. View Clinigen Group's earnings history. How often does Clinigen Group pay dividends? What is the dividend yield for Clinigen Group? Clinigen Group declared a dividend on Thursday, September 16th. Shareholders of record on Thursday, December 2nd will be given a dividend of GBX 5.46 per share on Tuesday, January 4th. This represents a dividend yield of 0.92%. The ex-dividend date is Thursday, December 2nd. This is a positive change from Clinigen Group's previous dividend of GBX 2.15. The official announcement can be seen at this link. View Clinigen Group's dividend history. Is Clinigen Group a good dividend stock? Clinigen Group(LON:CLIN) pays an annual dividend of GBX 0.08 per share and currently has a dividend yield of 0.82%. The dividend payout ratio of Clinigen Group is 0.53%. This payout ratio is at a healthy, sustainable level, below 75%. View Clinigen Group's dividend history. Who are Clinigen Group's key executives? Clinigen Group's management team includes the following people: Mr. Shaun Edward Chilton, CEO & Exec. Director (Age 54, Pay $662k)Richard Paling, Interim Chief Financial Officer & Group Financial ControllerMr. Sam Herbert, Chief Operating OfficerRob Fox, VP of Investor Relations & Corp. Devel.Ms. Amanda Miller, Gen. Counsel & Company Sec.Mr. David Bryant, Director of Corp. Devel.Jessica Archer, Global HR DirectorMr. Mark Corbett, Managing Director of Global Access DivisionMr. Johannes Willemse, Chief Commercial Officer (Age 54)Mr. Ivo Timmermans M.D., MBA, Chief Medial Officer (Age 62) Who are some of Clinigen Group's key competitors? Some companies that are related to Clinigen Group include Penumbra (PEN), CRISPR Therapeutics (CRSP), GN Store Nord A/S (GNNDY), Wound Management Technologies (WNDM), LHC Group (LHCG), Apellis Pharmaceuticals (APLS), Shandong Weigao Group Medical Polymer (SHWGF), Stevanato Group (STVN), Integra LifeSciences (IART), ConvaTec Group (CTEC), Hypera (HYPMY), Ginkgo Bioworks (DNA), Lantheus (LNTH), Evotec (EVT) and Guardant Health (GH). View all of CLIN's competitors. What other stocks do shareholders of Clinigen Group own? Based on aggregate information from My MarketBeat watchlists, some companies that other Clinigen Group investors own include Comerica (CMA), Honda Motor (HMC), Advanced Accelerator Applications (AAAP), Albemarle (ALB), First Hawaiian (FHB), Landec (LNDC), NII (NIHD), RTI International Metals (RTI), General Electric (GE) and NetApp (NTAP). What is Clinigen Group's stock symbol? Clinigen Group trades on the London Stock Exchange (LON) under the ticker symbol "CLIN." How do I buy shares of Clinigen Group? Shares of CLIN and other U.K. stocks can be purchased through online brokerage accounts that support trading on the London Stock Exchange (LSX). Some U.K. companies can be purchased through major U.S. brokerages in the form of American Depository Receipts (ADRs), which are placeholder equities held in a trust by a bank that represent shares of a foreign stock.Compare Top Brokerages Here. What is Clinigen Group's stock price today? One share of CLIN stock can currently be purchased for approximately GBX 925. How much money does Clinigen Group make? Clinigen Group (LON:CLIN) has a market capitalization of £1.23 billion and generates £565.60 million in revenue each year. How many employees does Clinigen Group have? Clinigen Group employs 1,000 workers across the globe. How can I contact Clinigen Group? Clinigen Group's mailing address is Pitcairn House Crown Square, First Avenue, STAFFORDSHIRE, DE14 2WW, United Kingdom. The official website for Clinigen Group is www.clinigengroup.com. The company can be reached via phone at +44-1283-495010. This page (LON:CLIN) was last updated on 6/29/2022 by MarketBeat.com Staff 30 Days of MarketBeat All Access for $1.00 Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your Risk-Free Trial Subscription Here Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Your Password: or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Choose a Password: Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply. MarketBeat Resources Premium Research Tools MarketBeat All Access subscribers can access stock screeners, the Idea Engine, data export tools, research reports, and other premium tools. Discover All Access Market Data and Calendars Looking for new stock ideas? Want to see which stocks are moving? View our full suite of financial calendars and market data tables, all for free. View Market Data Investing Education and Resources Receive a free world-class investing education from MarketBeat. Learn about financial terms, types of investments, trading strategies and more. Financial Terms Details Here
